Lipocine (NASDAQ:LPCN) Shares Cross Below 200-Day Moving Average – Here’s Why

Lipocine Inc. (NASDAQ:LPCN)’s share price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $5.60 and traded as low as $5.13. Lipocine shares last traded at $5.48, with a volume of 33,584 shares changing hands.

Wall Street Analyst Weigh In

LPCN has been the topic of several research analyst reports. Alliance Global Partners began coverage on shares of Lipocine in a report on Tuesday, September 24th. They issued a “buy” rating and a $10.00 target price on the stock. StockNews.com upgraded shares of Lipocine from a “hold” rating to a “buy” rating in a research note on Monday, October 14th.

Lipocine Stock Performance

The firm has a fifty day simple moving average of $4.48 and a two-hundred day simple moving average of $5.61. The firm has a market cap of $30.87 million, a PE ratio of -3.63 and a beta of 1.22.

Lipocine (NASDAQ:LPCN) last posted its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) earnings per share for the quarter. The company had revenue of $0.09 million for the quarter. Equities analysts forecast that Lipocine Inc. will post -0.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP bought a new stake in shares of Lipocine Inc. (NASDAQ:LPCN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.